sponsored
PatientsVille.com Logo

PatientsVille

Rheumatoid Arthritis Medical Research Studies

Up-to-date List of Rheumatoid Arthritis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Rheumatoid Arthritis Medical Research Studies

Rank Status Study
1 Recruiting Personalized Risk Estimator for Rheumatoid Arthritis Family Study
Condition: First Degree Relatives of Rheumatoid Arthritis Patients
Interventions: Behavioral: PRE-RA;   Behavioral: PRE-RA Plus;   Behavioral: General Rheumatoid Arthritis Education
Outcome Measure: Contemplation Ladder
2 Recruiting Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs);   Drug: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs);   Biological: UC-MSC+DMARDS
Outcome Measures: Safety of MSC treatment.;   RA Serology;   Disease Activity Score (DAS 28) Index Mean Change From Baseline;   Patient's assessment of pain.
3 Recruiting Evaluation of the Condition of Rheumatoid Arthritis After Treatment
Condition: Rheumatoid Arthritis
Intervention: Drug: The effectiveness of Xeljanz in Rheumatoid Arthritis patients
Outcome Measures: Change from baseline of clinical evaluation in Rheumatoid Arthritis;   Number of participants with adverse events
4 Unknown  Zostavax in Rheumatoid Arthritis
Conditions: Rheumatoid Arthritis;   Varicella Zoster
Intervention: Drug: Zostavax (varicella zoster virus) vaccine
Outcome Measures: safety;   Immunogenicity
5 Recruiting Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab
Condition: Moderate to Severe Rheumatoid Arthritis
Intervention: Biological: etanercept
Outcome Measures: To evaluate the efficacy of etanercept in adult subjects with moderate to severe Rheumatoid Arthritis who failed to respond or responded and then lost response to adalimumab as first biologic agent.;   Determine if anti-adalimumab antibodies predict response to etanercept, to determine if adalimumab failures predict response to etanercept, and to evaluate the effects of etanercept
6 Recruiting Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)
Condition: Rheumatoid Arthritis
Intervention: Drug: DMARD cessation
Outcome Measures: Time-to-flare of arthritis activity following DMARD cessation;   Clinical biomarkers predictive of DMARD-free remission;   Ultrasound biomarkers of DMARD-free remission;   Genetic biomarkers of DMARD-free remission;   Cytokine biomarkers of DMARD-free remission;   Rheumatoid arthritis disease activity;   Physical disability
7 Recruiting Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on Periodontium
Conditions: Rheumatoid Arthritis;   Periodontitis
Intervention: Other: oral exam and
Outcome Measures: Clinical attachment level;   Detection of periodontopathogenic germs;   Quantification of periodontopathogenic germs;   Detection of inflammation markers in the gingival fluid;   Quantification of inflammation markers in the gingival fluid;   Assessment of inflammation;   Assessment of oral hygiene level
8 Recruiting Discovering the Antecedents of Rheumatoid Arthritis Flare
Condition: Rheumatoid Arthritis
Intervention:
Outcome Measure: RNA transcripts that correlate with Rheumatoid Arthritis disease activity
9 Recruiting Full Mouth Disinfection and Antibiotics for Periodontitis in High Activity Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention:
Outcome Measures: Improvement in the Rheumatoid Arthritis disease activity index (DAS28ESR-3v) by >=1.2 points;   Improvement in the Rheumatoid Arthritis disease activity score (DAS28ESR-3v) by >=1.2 points;   Improvement in the Rheumatoid Arthritis disease activity score when with 3rd variable C reactive protein serum concentration (DAS28CRP-3v) by >=1.2 points;   Improvement in the clinical disease activity index cDAI;   Improvement in the simplified disease activity index cDAI;   Number of patients with 20%, 50% or 70% improvement in the American College of Rheumatology (ACR) response criteria;   Number of patients in ACR/EULAR remission;   % change of B-mode (= gray-scale) and Power-Doppler signals to baseline;   Reduction in the probing pocket depth (PPD) in moderately deep (PPD >/= 4mm) und deep periodontal pockets (PPD > 6mm);   Improvement in clinical attachment level (CAL), as the sum of PPD plus gingival recession (GR);   Reduction in the number of sites with bleeding on probing (BoP)
10 Recruiting Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention: Drug: Rituximab
Outcome Measures: Number of patients who have reached ACR20 within 24 weeks after the treatment initiation;   Frequency of adverse events (AE) and serious adverse events (SAE) that is related, in Investigator's opinion, to Rheumatoid Arthritis therapy;   Frequency of AE and SAE grade 3-4 that is related, in Investigator's opinion, to Rheumatoid Arthritis therapy;   Number of cases of early withdrawal from the study caused by AE or SAE;   Level of binding and neutralizing antibodies to rituximab in patients from both groups;   CD19+ and CD20+ lymphocyte counts
11 Unknown  Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis
Conditions: Apoptotic DNA Damage;   Rheumatoid Arthritis;   T-cell Lymphocytosis
Interventions: Drug: Group 1 or Orencia treated group;   Other: Group 2 (DMARDS treated group)
Outcome Measures: To measure the change in apoptosis of T cells, B cells and antigen presenting (APC) cells in Rheumatoid Arthritis between the baseline, 3 months and at 6 months time points;   To measure the change in disease activity score (DAS28) between the baseline, 3 months and 6 months time points
12 Recruiting Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
Conditions: Rheumatoid Arthritis;   Ankylosing Spondylitis;   Psoriatic Arthritis;   Crohn´s Disease;   Ulcerative Colitis;   Plaque Psoriasis
Intervention:
Outcome Measures: Changes in the Beliefs about Medicines Questionnaire (BMQ) for Rheumatoid Arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis patients (AS), plaque psoriasis (PsO), Crohn's disease (CD) and ulcerative colitis (UC):;   Changes of the Treatment Satisfaction Questionaire for Medication (TSQM) over time.;   Changes in Rheumatoid Arthritis Disease Activity Index in patients with Rheumatoid Arthritis and if reasonable in patients with psoriasis arthritis;   Changes in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with ankylosing spondylitis;   Changes in Erythrocyte Sedimentation Rate (ESR) over time;   Changes in C-reactive protein (CRP) over time;   Changes in Morisky Medication Adherence Scale (MMAS) for Rheumatoid Arthritis, psoriatic arthritis, ankylosing spondylitis patients.;   Changes in Psoriasis Area and Severity Index (PASI) in patients with plaque psoriasis;   Changes in Harvey-Bradshaw Index (HBI) for patients with CD.;   Changes in Partial Mayo Score (PMS) for patients with UC.
13 Recruiting A Study of Subjects With Rheumatoid Arthritis Who Are in Clinical Remission to Investigate Patient and Disease Characteristics That Could Help Identify Which Subjects Could Reduce Their Adalimumab Dose Without Flaring
Conditions: Rheumatoid Arthritis;   Musculoskeletal and Connective Tissue Diseases
Interventions: Drug: Adalimumab;   Other: Placebo
Outcome Measures: Hand and wrist synovitis Rheumatoid Arthritis magnetic resonance imaging (MRI) scoring system (RAMRIS) score;   Bone Marrow Edema (BME) RAMRIS score;   Composite of Hand, Wrist and BME RAMRIS scores;   Flare occurrence;   Time to flare;   Flare severity;   Proportion of subjects who regain clinical remission in the Open-Label Rescue Arm over time;   Time to regain clinical remission in the Open-Label Rescue Arm;   Proportion of subjects who achieve low disease activity in the Open-Label Rescue Arm over time;   Change in DAS28 (ESR);   Proportion of subjects maintaining clinical remission throughout the study;   Change in MRI synovitis;   Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) over time in the open-label rescue arm;   Proportion of subjects with HAQ-DI normal;   Change in RAPID 3 scores assessed during in-office visits;   Change in RAPID 3 at home assessments;   Change in Treatment Satisfaction Questionnaire for Medication (TSQM) in the open-label rescue arm;   Change in Work Productivity and Activity Impairment (WPAI);   Change in Short Form-36 (SF-36);   Change in Functional Assessment of Chronic Illness Therapy - fatigue (FACIT-fatigue);   Clinical Disease Activity Index (CDAI);   Change in Simplified Disease Activity Index (SDAI);   Change in BME;   Change in erosions RAMRIS scores
14 Unknown  A Study Evaluating the Safety and Efficacy of Cura-100 in Subjects With Rheumatoid Arthritis and Osteoarthritis
Conditions: Rheumatoid Arthritis;   Osteoarthritis
Intervention: Drug: Cura-100
Outcome Measures: The primary outcome is remission of Rheumatoid Arthritis and osteoarthritis, which will be measured with ACR criteria.;   The secondary outcome is the reduction in signs and symptoms of Rheumatoid Arthritis and osteoarthritis for a continuous three or six month period, measured with ACR20 and the change from baseline in HAQ.
15 Not yet recruiting ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
Condition: Rheumatoid Arthritis
Interventions: Drug: ACTHAR;   Drug: NSAID
Outcome Measures: Improvement in disease activity as measured by ACR20 and ACR50.;   adverse events
16 Not yet recruiting Causes of Comorbid Infertility Among Women With Rheumatoid Arthritis
Conditions: Infertility;   Rheumatoid Arthritis
Intervention:
Outcome Measures: Ovarian Reserve between women with and without RA;   Ovulation Frequency between women with and without RA;   Rates of Infertility between women with and without RA;   Number of Pregnancies between women with and without RA;   Age at attempted and actual conception between women with and without RA
17 Recruiting Patient Rheumatoid Arthritis Social Support Study
Condition: Rheumatoid Arthritis
Intervention: Behavioral: Peer Support Program
Outcome Measures: change in functional status;   change in medication adherence;   change in self-efficacy;   change in fatigue;   change in pain
18 Recruiting The Effects of Cardiac Rehabilitation on Cardiovascular Disease Risk in Rheumatoid Arthritis Patients
Condition: Rheumatoid Arthritis
Intervention: Behavioral: Exercise
Outcome Measures: Framingham risk score;   Levels of systemic inflammation;   Severity of rheumatoid arthritis;   Weight;   Waist girth;   Resting heart rate;   Resting blood pressure;   Lipid profile;   Fasting glucose;   Aerobic fitness;   Physical activity level;   Functional ability;   Smoking history;   Alcohol consumption
19 Recruiting Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients
Condition: Rheumatoid Arthritis
Interventions: Biological: CFZ533;   Drug: Placebo
Outcome Measures: Number of patients with adverse events as a measure of safety and tolerability;   Plasma Pharmacokinetics (PK) of CFZ533: Area Under the Plasma Concentration-time Curve (AUC);   Plasma Pharmacokinetics (PK) of CFZ533: Observed Maximum Plasma Concentration Following Drug Administration (Cmax);   Plasma Pharmacokinetics (PK) of CFZ533: Systemic Clearance from Plasma (CL);   Plasma Pharmacokinetics (PK) of CFZ533: Apparent Volume of Distribution (Vss);   CFZ533 immunogenicity
20 Recruiting Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention:
Outcome Measures: Number of missed working days; self assessed workability; severity of clinical symptoms (number of tender and swollen joints), C-reactive Protein; severity of functional impairment; assessment of quality of life. Safety: Analysis of adverse events.;   Number and duration of hospitalization; number of days of impairment of non-professional activities; self-assessment of therapy in comparison to previous therapies.

These studies may lead to new treatments and are adding insight into Rheumatoid Arthritis etiology and treatment.

A major focus of Rheumatoid Arthritis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Rheumatoid Arthritis